1.1. Genesis of the Company
The BOOMERANG venture is rooted in Mr. Davis's management experience within the pharmaceutical industry, combined with Mr. Crassard's educational background and in-depth research on business opportunities in the pharmaceutical industry.
1.2. The Team
At the Groupe ESC Lyon MBA program in France, Mr. Davis and Mr. Crassard met two other pharmaceutical industry professionals - Mr. Bueb and Mr. Samayoa - with complementary skills/experience determined to launch a company in the pharmaceuticals field. Mr. Bueb is a chemical engineer with work experience at Hoffmann-La Roche in Basle and personal contacts at Novartis. Mr. Crassard is a pharmacist with entrepreneurial experience and personal contacts in European healthcare. Mr. Samayoa has professional experience in the European pharmaceuticals industry and personal contacts at Novartis. From this base, the team has developed high-level contacts at: Novartis, Hoechst, Hoffmann-La Roche, SmithKline Beecham, Bayer, Rhone-Poulenc Rorer, Lipha, and Synthelabo.
1.3. The Inspiration
Mr. Davis joined a US start-up company in 1990 that provides standard communications programs (ex, brochures, symposia organization, slide kits) to pharmaceutical companies. This company is operational today with excellent profit margins and little differential advantage.
Based on the success story of Mr. Davis's previous company, BOOMERANG's partners have conducted in-depth research to determine whether the provision of standard communications programs to the European pharmaceutical industry presents a similar business opportunity.
1.4. Discovery of the Market Opportunity
The partner's research has shown that although there is money to be made in the provision of standard communications programs to pharmaceutical companies, there are a large number of competitors who provide these services in Europe. Although the strong market growth of the pharmaceutical industry will support additional sales for standard communications programs, a significant proportion of sales would come at the expense of competing vendors.
In order to avoid a zero-sum market, BOOMERANG has carefully synthesized the stated communications needs of several of the largest European pharmaceutical companies and has determined that there is an excellent market for the provision of pharmaceutical communications programs designed specifically for broadcast via innovative, interactive media (such as Internet).
|Table of Contents||Appendices|
0. Executive Summary|
1. The Company
2. Market Characteristics
3. Market Analysis
4. Competitive Strategy
5. Company Strategy
6. Marketing Plan
7. Production Plan
9. Financial Analysis
Internet Site Study
Letters of Intent
|All information herein is confidential and proprietary to Boomerang.|